JPRN-UMIN000024201Enrolling By Invitation未知
Evaluation of effects of Ra-223 chloride therapy for bone metastasis of prostate cancer by quantitative bone SPECT/CT
试验速览
- 阶段
- 未知
- 状态
- Enrolling By Invitation
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Male
入选标准
- •? A patient with bone metastasis of castration resistant prostate cancer
- •? A patient without known massive metastatic lesion except bone metastasis
- •? A patient who is done or planned a quantitative bone SPECT/CT within 30 days before the initial administration of Ra-233 therapy
- •? A patient who consents to this study on the document form
排除标准
- •? A patient with worse bone marrow dysfunction more than WHO grade III
- •? A patient with any massive metastatic lesion except bone, such as brain, lung or liver
- •? A patient who received radiation therapy or surgical therapy within 30 days, or who plans either therapy
- •? A patient who deny the prosecution of this study in the middle of the study
研究者
相似试验
已完成
不适用
The study of combination therapy with radium-223 and enzalutamide in Osaka City UniversityCastration-resistant prostate cancer with bone metastasesJPRN-UMIN000029422Osaka City University Graduate School of Medicine10
招募中
不适用
Efficacy and Safety of Ra-223 as 1st line therapy in combination with alternative anti-androgen therapy for bone metastatic CRPC PatientsJPRN-UMIN000030946Chiba University30
进行中（未招募）
1 期
A study investigating the safety of radium-223 dichloride, given as a 50kBq/kg dose every four weeks to patients with castration-resistant prostate cancer that has spread to bone, who have already been treated with a course of six doses of radium-223 dichloride 50kBq/kg every four weeks.EUCTR2013-003046-17-GBBayer HealthCare AG44
进行中（未招募）
1 期
A study investigating the safety of radium-223 dichloride, given as a 50kBq/kg dose every four weeks to patients with castration-resistant prostate cancer that has spread to bone, who have already been treated with a course of six doses of radium-223 dichloride 50kBq/kg every four weeks.Castration Resistant Prostate cancer patients with bone metastasesMedDRA version: 16.1Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 100000004864EUCTR2013-003046-17-SEBayer HealthCare AG40
进行中（未招募）
1 期
A study investigating the safety of radium-223 dichloride, given as a 50kBq/kg dose every four weeks to patients with castration-resistant prostate cancer that has spread to bone, who have already been treated with a course of six doses of radium-223 dichloride 50kBq/kg every four weeks.Castration Resistant Prostate cancer patients with bone metastasesMedDRA version: 19.0Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 100000004864EUCTR2013-003046-17-DEBayer AG40